DDInter1141 DDInter1094
17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione. A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC.
Megestrol acetate {u} (Compound) resembles {v} (Compound) Progesterone
Progesterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Megestrol acetate {u} (Compound) resembles {v} (Compound) Testosterone
Testosterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Megestrol acetate {u} (Compound) resembles {v} (Compound) Progesterone
Progesterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lorlatinib
Megestrol acetate {u} (Compound) resembles {v} (Compound) Testosterone
Testosterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acetohexamide
Acetohexamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Megestrol acetate {u} (Compound) resembles {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} may lead to a major life threatening interaction when taken with {v} Bexarotene
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lorlatinib
Megestrol acetate {u} (Compound) resembles {v} (Compound) Dydrogesterone
Dydrogesterone {u} (Compound) resembles {v} (Compound) Testosterone
Testosterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Megestrol acetate {u} (Compound) resembles {v} (Compound) Progesterone
Progesterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acetohexamide
Acetohexamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Megestrol acetate {u} (Compound) resembles {v} (Compound) Fludrocortisone
Fludrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acetohexamide
Acetohexamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Megestrol acetate {u} (Compound) resembles {v} (Compound) Testosterone
Testosterone {u} may lead to a major life threatening interaction when taken with {v} Warfarin
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Megestrol acetate {u} (Compound) resembles {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rosuvastatin
Rosuvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Megestrol acetate (Compound) resembles Progesterone (Compound) and Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Megestrol acetate (Compound) resembles Testosterone (Compound) and Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Megestrol acetate (Compound) resembles Progesterone (Compound) and Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Megestrol acetate (Compound) resembles Testosterone (Compound) and Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Megestrol acetate (Compound) resembles Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Megestrol acetate (Compound) resembles Dydrogesterone (Compound) and Dydrogesterone (Compound) resembles Testosterone (Compound) and Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Megestrol acetate (Compound) resembles Progesterone (Compound) and Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Megestrol acetate (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Megestrol acetate (Compound) resembles Testosterone (Compound) and Testosterone may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Megestrol acetate (Compound) resembles Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may cause a minor interaction that can limit clinical effects when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib